Literature DB >> 15027049

Molecular targets of botulinum toxin at the mammalian neuromuscular junction.

Dorothy D Whelchel1, Tonia M Brehmer, Paula M Brooks, Neely Darragh, Julie A Coffield.   

Abstract

The molecular targets of botulinum neurotoxins (BoNTs) are SNARE (soluble N-ethylmaleimide-sensitive factor-attachment protein-receptor) proteins necessary for neurotransmitter release. BoNT are powerful therapeutic agents in the treatment of numerous neurological disorders. The goals of this study were to (1) assess toxin diffusion by measuring substrate cleavage in adjacent and distant muscles, and (2) characterize the clinical course using SNARE protein chemistry. A small volume of BoNT/A was injected unilaterally into the mouse gastrocnemius muscle. Motor impairment was limited to the toxin-treated limb. No systemic illness or deaths occurred. At five time points, a subset of mice were killed, and muscles from both hindlimbs, and the diaphragm, were collected. Protein samples were examined for changes in SNAP-25 (synaptosomal-associated protein of Mr = 25 kDa) using immunochemistry. SNAP-25 cleavage product was noted in the toxin-treated limb as early as 1 day postinjection and continued through day 28. Onset and peak levels of substrate cleavage corresponded to the onset and peak clinical response. Cleavage was observed in adjacent and distant muscles, demonstrating that substrate cleavage is a sensitive indicator of toxin diffusion. Significant increases in full-length SNAP-25 and vesicle-associated membrane protein II were evident early in the impaired limb and continued through day 28. The increased SNARE protein most likely originates from nerve terminal sprouts. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027049     DOI: 10.1002/mds.20004

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

Review 1.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 2.  Modern management of obstructive salivary diseases.

Authors:  P Capaccio; S Torretta; F Ottavian; G Sambataro; L Pignataro
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-08       Impact factor: 2.124

3.  Botulinum toxin type A in the healing of chronic lesion following bilateral spasticity of gluteus muscle.

Authors:  Emanuele Cigna; Michele Maruccia; Benedetta Fanelli; Nicolò Scuderi
Journal:  Int Wound J       Date:  2012-10-19       Impact factor: 3.315

4.  Takotsubo-like Myocardial Dysfunction in a Patient with Botulism.

Authors:  Shuichi Tonomura; Yoshiaki Kakehi; Masatoshi Sato; Yuki Naito; Hisao Shimizu; Yasunobu Goto; Nobuyuki Takahashi
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

5.  Botulinum Toxin Injection-Site Selection for a Smooth Shoulder Line: An Anatomical Study.

Authors:  Je Hun Lee; Key Youn Lee; Ji Young Kim; Woo Hyeon Son; Ji Heun Jeong; Young Gil Jeong; Seongoh Kwon; Seung Ho Han
Journal:  Biomed Res Int       Date:  2017-01-26       Impact factor: 3.411

6.  Treatment of primary axillary hyperhidrosis with botulinum toxin type a: our experience in 50 patients from 2007 to 2010.

Authors:  Stefano Scamoni; Luigi Valdatta; Claudia Frigo; Francesca Maggiulli; Mario Cherubino
Journal:  ISRN Dermatol       Date:  2012-10-17

7.  Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells.

Authors:  Regina Clare Meyer Whitemarsh; William Howard Tepp; Eric Arthur Johnson; Sabine Pellett
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.